

Price	N 2.01
FVE (last communicated)	N 2.07
52-week range	₩ 1.41 - 2.65
Market Cap. (N 'bn)	39,803
1-month Avg. Vol	9,929,044
Curr. PB	0.21x

FCMB:NL - Share Price Trend



Emmanuel Adeleke Emmanuel.Adeleke@arm.com.ng

FCMB Group Plc. (FCMB.NL)

Initial View

Earnings below par

- FCMB Group Plc released its long awaited 9M 19 audited result last week Friday with earnings (-4.8% YoY to N10.8 billion) faltering over the same period, largely on account of lower Non-Interest Revenue. Although, comparing with our FY 19 estimates, the 9M result printed relatively higher¹; we believe the performance was still below par. For context, despite a significant moderation in loan loss provision and an unusual gain in Other Income, weak NIM together with lower FX revaluation gains restrained earnings growth over the period. In addition, reflecting an impact of reduced fees in the Pensions sector, earnings from the asset & wealth management declined by 7% YoY, contributing 9% to the group's income.
- Streamlining to the quarterly figures, FCMB recorded its lowest EPS since Q2 2018. Specifically, despite an unusual gain of about N4.9 billion in Other Income, both PBT and PAT declined 11.8% and 16.6% QoQ respectively driven by lower interest income recorded during the quarter.
- Despite a moderation in funding cost, asset yield fell faster with interest income declining by 12.7% QoQ to N31.4 billion. Key driver for the reduced interest income was a 21.4% QoQ decline in interest income on loans with related asset yield falling 160 bps QoQ. Net impact of the above resulted to a 68-bps compression in NIM with NII also moderating 12.3% QoQ to N17.6 billion. Elsewhere, NIR jumped 60.4% QoQ to N12.3 billion, reflecting an unusual gain in Other Income line. Asset quality improved better than we expected with NPL ratio coming in at 3.5% (FY 18: 5.9%) and cost of risk improving to 1.6% (-160 bps YoY and -14 bps QoQ). Consequently, loan loss provisioning booked by the bank declined by 26.8% QoQ to N2.4 billion. We would be getting more clarity from management on the improvement in asset quality as well as the jump in Other Income.
- We are quite impressed with the improvement in the bank's asset quality; however, we note the sluggish growth in the bank's gross loan book (-1.3% YTD, +1.5% QoQ) in spite of CBN's coercion on DMBs' via the minimum loan to funding requirement. For context, FCMB reported a loan to funding ratio of 57.4% as at Q3 19 (Q2 19: 51.7%), coming below the revised minimum loan to funding requirement of 65%.

¹ Due to lower than expected provisioning

- For us, we think the weak credit growth could be linked with the bank's relatively low CAR which improved slightly over Q3 19 (Q3 19: 17.9%, Q2 19: 16.3%). Nonetheless, we would be seeking clarity from management on what they intend to do to meet up with the requirement on or before December 31st.
- The stock currently trades at a current P/B of 0.21x which is at a discount to FIDELITY of 0.27x. Our last communicated FVE on FCMB is N2.07 which translates to a NEUTRAL rating on the stock. We will be revisiting our numbers after meeting with management.
- 9M 2019 analyst and investors conference call: FCMB would be hosting a conference call on Thursday,
 5 December at 15.00 Lagos and 14.00 London time. For more details, <u>click here.</u>

N'million	9M 2019	9M 2018	YoY (pps)	Q3 19	Q2 19	QoQ
Gross Earnings	135,824	132,875	2.22%	46,038	45,882	0.34%
Net Interest Income	56,231	53,235	5.63%	17,577	20,036	-12.27%
Non-Interest Revenue	27,618	33,029	-16.38%	12,266	7,646	60.43%
Operating Expenses	(63,194)	(56,870)	11.12%	(23,503)	(19,949)	17.81%
Impairment	(7,852)	(14,627)	-46.32%	(2,353)	(3,213)	-26.76%
РВТ	12,803	14,767	-13.30%	3,987	4,520	-11.78%
PAT	10,791	11,341	-4.85%	3,262	3,912	-16.61%
EPS	0.54	0.57	-4.85%	0.16	0.20	-16.61%
N'million	9M 2019	9M 2018	YoY	Q3 19	Q2 19	QoQ
Loans	638,065	601,852	6.02%	638,065	617,909	3.3%
Total Assets	1,516,155	1,295,024	17.08%	1,516,155	1,512,125	0.3%
Deposits	863,440	755,891	14.23%	863,440	822,992	4.9%
Total Liabilities	1,328,191	1,116,082	19.00%	1,328,191	1,323,134	0.4%
Key Ratios	9M 2019	9M 2018	change (pps)	Q3 19	Q2 19	change (pps)
Assets Yields	10.76%	11.48%	-0.72%	10.03%	11.84%	-1.81%
WACF	5.03%	5.77%	-0.74%	4.53%	5.34%	-0.80%
Net Interest Margin	5.95%	6.41%	-0.46%	6.91%	7.59%	-0.68%
Cost-Income Ratio	75.37%	65.93%	9.44%	78.75%	72.07%	6.69%
Cost of Risk	1.64%	3.24%	-1.60%	1.48%	2.08%	-0.60%
ROAE	7.63%	8.50%	-0.86%	6.97%	8.46%	-1.49%

Summary of Results

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

TOP 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% 20 %	NEUTRAL	5% - 20 %
NEUTRAL	0% 10 %	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

RECOMMENDATION KEY			
Rating	Recommendation		
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations		
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight		
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reas portfolio constraints		
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting		
SELL	Sell-off security completely from portfolio		

Copyright © 2019 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.